Publications by authors named "N Hashemi-Sadraei"
Immune checkpoint inhibitors (ICI) revolutionized cancer therapy by augmenting anti-tumor immunity via cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1/programmed death-ligand 1 (PD-1/PD-L1). However, this breakthrough is accompanied by immune-related adverse effects (irAEs), including renal complications. ICI-related nephritis involves complex mechanisms like auto-reactive T cells, auto-antibodies, reactivation of drug-specific T cells, and cytokine-driven inflammation culminating in AKI.
View Article and Find Full Text PDFBackground: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) are widely used in the treatment of metastatic malignancies. Judiciously balancing disease control (DC) against development of immune-related adverse events (irAE) remains a crucial aspect of treatment. The effect of treatment discontinuation after sustained disease control (SDC) is unknown.
View Article and Find Full Text PDFArticle Synopsis
- Tarlatamab (AMG 757) is a new treatment for small-cell lung cancer (SCLC) that targets DLL3 and CD3, leading to tumor destruction through T-cell activation.
- In a phase I study involving 107 patients with relapsed/refractory SCLC, results showed a 23.4% objective response rate, with manageable safety issues and a median duration of response of 12.3 months.
- The findings indicate that tarlatamab may be a promising treatment option for heavily pretreated SCLC patients, warranting further research, especially in patients with higher DLL3 expression.
Article Synopsis
- Effective treatments for small-cell/neuroendocrine prostate cancer (t-SCNC) are lacking, but DLL3 is identified as a key marker associated with poor survival rates in these patients.
- Researchers developed a PET agent to detect DLL3 and found that the immunotherapy AMG 757 effectively targets and kills DLL3-expressing cancer cells in preclinical models.
- Clinical trials are underway for AMG 757, showing promising results, including a partial response in a patient, highlighting DLL3 as a viable therapeutic target in aggressive prostate cancer subtypes.
Background: Given the dearth of data regarding the time to treatment initiation (TTI) in the palliative setting, and its impact on survival outcomes, we sought to determine TTI in a real-world cohort of metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer (mPC) patients and evaluate the impact of TTI on real-world survival outcomes.
Methods: We collected survival and treatment data for mCRC and mPC from the Flatiron Health electronic health records (EHR) derived database. We divided TTI into 3 categories: < 2 weeks, 2-< 4 weeks, and 4-8 weeks, from diagnosis to first-line therapy.